Pfizer Stops Enrollment in Paxlovid Trial in Standard-Risk Population
Pfizer Inc said on Tuesday it would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after data analysis showed a non-significant reduction in hospitalizations and deaths.